Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.61 |
| ▸ | EGFR | P00533 | 10/20 | 0.61 |
| ▸ | LCK | P06239 | 8/20 | 0.61 |
| ▸ | ITK | Q08881 | 7/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.50 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14575445 | 1.00 | BTK (0.61) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14575421 | 0.92 | BTK (0.57) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14575420 | 0.92 | BTK (0.57) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14575357 | 0.91 | BTK (0.56) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14575359 | 0.91 | BTK (0.56) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14693595 | 0.88 | SRC (0.55) | BTKEGFRLCKITKSRC | |
| SCHEMBL14693592 | 0.88 | SRC (0.55) | BTKEGFRLCKITKSRC | |
| SCHEMBL14575859 | 0.84 | BTK (0.55) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14575862 | 0.84 | BTK (0.55) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14576269 | 0.83 | BTK (0.55) | BTKEGFRLCKITKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862722-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862722-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 947/4885LCK 19/4885 |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885EGFR 947/4885LCK 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.